1. Nesiritide, Heart Failure, and Renal Dysfunction: Irrational Exuberance or Throwing the Baby out with the Bathwater

   • Ronald M. Witteles

   Editorial 08 April 2009 Pages: 183 - 186

2. Pharmacological Approaches to Modifying HDL: More Basic Science to Understand HDL Metabolism is Necessary

   • Michael H. Davidson

   Editorial 12 May 2009 Pages: 187 - 188

3. Dofetilide as Activator of Na/Ca Exchange: New Perspectives on an ‘Old’ Drug

   • Gudrun Antoons
   • Karin R. Sipido

   Editorial 02 April 2009 Pages: 189 - 192

4. Remote Postconditioning is More Potent than Classic Postconditioning in Reducing the Infarct Size in Anesthetized Rabbits

   • G. Gritsopoulos
   • E. K. Iliodromitis
   • D. T. Kremastinos

   OriginalPaper 03 March 2009 Pages: 193 - 198

   

5. NO-1886 Up-regulates Niemann–Pick C1 Protein (NPC1) Expression Through Liver X Receptor α Signaling Pathway in THP-1 Macrophage-Derived Foam Cells

   • Xin Ma
   • Yan-Wei Hu
   • Chao-Ke Tang

   OriginalPaper 20 February 2009 Pages: 199 - 206

   

6. Dofetilide Enhances the Contractility of Rat Ventricular Myocytes via Augmentation of Na⁺–Ca²⁺ Exchange

   • Xuan-Ping Zhang
   • Bo-Wei Wu
   • Ming-Sheng Zhang

   OriginalPaper 17 February 2009 Pages: 207 - 214

   

7. Native LDL-Cholesterol Mediated Monocyte Adhesion Molecule Overexpression is Blocked by Simvastatin

   • Carlos V. Serrano Jr.
   • Antônio Eduardo Pesaro
   • Hugo P. Monteiro

   OriginalPaper 06 January 2009 Pages: 215 - 220

   

8. Impact of Nesiritide on Renal Function and Mortality in Patients Suffering from Heart Failure

   • Ioannis D. Dontas
   • Theodoros Xanthos
   • Lila Papadimitriou

   OriginalPaper 28 February 2009 Pages: 221 - 233

9. More Clinical Lessons from the FIELD Study

   • Sergio Fazio

   Review 22 January 2009 Pages: 235 - 241

   

10. Randomised, Double-Blind, Placebo-Controlled Trial of Ivabradine in Patients with Acute Coronary Syndrome: Effects of the I _f Current Inhibitor Ivabradine on Reduction of Inflammation Markers in Patients with Acute Coronary Syndrome—RIVIERA Trial Study Design and Rationale

    • Alberto Dominguez-Rodriguez
    • Sima Samimi Fard
    • Juan Carlos Kaski

    OriginalPaper 20 February 2009 Pages: 243 - 247

    

11. Agreement of Swiss-Adapted International and European Guidelines for the Assessment of Global Vascular Risk and for Lipid Lowering Interventions

    • Michel Romanens
    • Franz Ackermann
    • Matthias Schwenkglenks

    OriginalPaper 29 January 2009 Pages: 249 - 254

    

12. ISCP President’s Page

    • Jay N. Cohn

    OriginalPaper 03 March 2009 Pages: 255 - 256

13. Obituary of Philip Poole-Wilson, Member of the Board of Directors of the International Society of Cardiovascular Pharmacotherapy

    • Inder Anand

    Obituary 07 May 2009 Pages: 257 - 259